当飞利肝宁胶囊联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化的疗效观察

目的探讨当飞利肝宁胶囊联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化的临床疗效。方法选择2013年6月—2015年6月南京鼓楼医院集团宿迁市人民医院感染科收治的慢性乙型肝炎肝纤维化患者98例,随机分为对照组和治疗组,每组各49例。对照组口服扶正化瘀胶囊,5粒/次,3次/d。治疗组患者在对照组治疗基础上口服当飞利肝宁胶囊,4粒/次,3次/d。两组患者均连续治疗6个月。观察两组治疗前后透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(ⅣC)、门静脉直径、脾脏厚度、脾静脉直径、肝纤维化分期评分、丙氨酸氨基转移酶(ALT)、HBV-DNA的变化情况。结果治疗后,两组患者HA、LN、PCⅢ、ⅣC均显著降低,同组治疗前后差异有统计学意义(P0.05);治疗后,治疗组HA、LN、PCⅢ、ⅣC低于对照组,两组比较差异具有统计学意义(P0.05)。两组门静脉直径、脾脏厚度、脾静脉直径明显减小,同组治疗前后差异有统计学意义(P0.05);治疗后,治疗组门静脉直径、脾脏厚度小于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组肝纤维化分期、HBV-DNA水平、ALT均显著降低,同组治疗前后差异有统计学意义(P0.05);治疗后,治疗组肝纤维化分期、HBV-DNA水平、ALT均低于对照组,两组比较差异具有统计学意义(P0.05)。对照组和治疗组的ALT复常率分别为93.88%、100.00%,两组比较差异具有统计学意义(P0.05)。结论当飞利肝宁胶囊联合扶正化瘀胶囊治疗慢性乙型肝炎肝纤维化有协同作用,可显著改善肝功能,降低肝纤维化指标,具有一定的临床推广应用价值。

Clinical observation of Dangfei Liganning Capsules combined with Fuzheng Huayu Capsules in treatment of chronic hepatitis B with liver fibrosis

Objective To investigate the clinical effect of Dangfei Liganning capsules combined with Fuzheng Huayu Capsules in treatment of chronic hepatitis B with liver fibrosis.Methods Patients (98 cases) with chronic hepatitis B with liver fibrosis in Department of Infectious Disease of Suqian People’s Hospital co., LTD of Nanjing Gulou Hospital Group from June 2013 to June 2015 were randomly divided into control and treatment groups, and each group had 49 cases. The patients in the control group werepo administered with Fuzheng Huayu Capsules, 5 grains/time, three times daily. The patients in the treatment group werepo administered with Dangfei Liganning Capsules on the basis of the treatment group, 4 grains/time, three times daily. The patients in two groups were treated for 6 months. After treatment, the changes of HA, LN, PCⅢ,Ⅳ C, portal vein diameter, spleen thickness, spleen vein diameter, scores of liver fibrosis stage, ALT, and HBV-DNA in two groups before and after treatment were compared.Results After treatment, HA, LN, PCⅢ, andⅣ C in the two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). After treatment, HA, LN, PCⅢ, andⅣ C in the treatment group were lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, portal vein diameter, spleen thickness, and spleen vein diameter in the two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). After treatment, portal vein diameter and spleen thickness in the treatment group were less than those in the control group, with significant difference between two groups (P < 0.05). After treatment, liver fibrosis stage, HBV-DNA, and ALT in the two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). After treatment, liver fibrosis stage, HBV-DNA, and ALT in the treatment group were lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the ALT normalization rates in the control and treatment groups were 93.88%and 100.00%, respectively, and there were differences between two groups (P < 0.05).Conclusion Dangfei Liganning capsules combined with Fuzheng Huayu Capsules has synergistic effects in treatment of chronic hepatitis B with liver fibrosis, and can significantly improve liver function, and reduce the liver fibrosis indexes, which has a certain clinical application value.